Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Key Laboratory of Hematology of Nanjing Medical University, Nanjing, China.
Br J Haematol. 2022 Mar;196(6):1353-1361. doi: 10.1111/bjh.18000. Epub 2021 Dec 28.
To assess the prognostic significance of immunoglobulin (Ig) paraproteinaemia in mucosa-associated lymphoid tissue (MALT) lymphoma, 218 patients diagnosed with MALT lymphoma were enrolled in this study. Serum Ig paraprotein was detected in 42 of 218 patients (19.3%), mostly IgM-K (15, 35.7%), followed by IgM-L and IgG-L. Advanced age (p = 0.025), poor Eastern Cooperative Oncology Group performance status (p = 0.014), bone marrow involvement (p = 0.019), B symptoms (p = 0.039), advanced disease stage (III-IV) (p < 0.0001), elevated serum β2-microglobulin level (p < 0.0001), multiple extranodal sites of involvement (p < 0.0001), nodal involvement (p < 0.0001), systemic therapy (p < 0.0001) and higher MALT-lymphoma International Prognostic Index (MALT-IPI) scores (p = 0.001) were significantly associated with the presence of serum Ig paraprotein. Multivariate Cox regression analysis showed that Ig paraproteinaemia was an independent prognostic predictor for inferior progression-free survival (PFS) and overall survival. A new prognostic index based on MALT-IPI and Ig paraproteinaemia, as assessed using receiver operating characteristic curves and the area under the curve statistics, showed better discriminative ability than MALT-IPI in predicting PFS. In conclusion, Ig paraproteinaemia was a promising prognostic predictor for MALT lymphoma. Ig paraproteinaemia together with MALT-IPI might contribute to optimising therapeutic management in clinical practice.
为了评估免疫球蛋白(Ig)副蛋白血症在黏膜相关淋巴组织(MALT)淋巴瘤中的预后意义,本研究纳入了 218 例 MALT 淋巴瘤患者。在 218 例患者中,有 42 例(19.3%)检测到血清 Ig 副蛋白,主要为 IgM-K(15 例,35.7%),其次为 IgM-L 和 IgG-L。高龄(p=0.025)、较差的东部肿瘤协作组体力状况(p=0.014)、骨髓累及(p=0.019)、B 症状(p=0.039)、晚期疾病分期(III-IV 期)(p<0.0001)、血清β2-微球蛋白水平升高(p<0.0001)、多个结外累及部位(p<0.0001)、淋巴结累及(p<0.0001)、全身治疗(p<0.0001)和较高的 MALT 淋巴瘤国际预后指数(MALT-IPI)评分(p=0.001)与血清 Ig 副蛋白的存在显著相关。多因素 Cox 回归分析显示,Ig 副蛋白血症是无进展生存(PFS)和总生存的独立预后预测因素。一项基于 MALT-IPI 和 Ig 副蛋白血症的新预后指数,通过接受者操作特征曲线和曲线下面积统计评估,在预测 PFS 方面显示出比 MALT-IPI 更好的区分能力。总之,Ig 副蛋白血症是 MALT 淋巴瘤有前途的预后预测因素。Ig 副蛋白血症与 MALT-IPI 联合使用可能有助于优化临床实践中的治疗管理。